Merck + Co., Inc.

Amgen Inc.

Other

E.i. Dupont De Nemours and Company

Robert D Larsen

Ian W Davies

Thomas R Verhoeven

Kai Rossen

Philip J Pye

Edward G Corley

Daniel Richard Sidler

Michel Journet

Anthony O King

Cheng Yi Chen

Chris H Senanayake

Cheng-Yi Chen

Linda Gerena

Paul J Reider

Dongwei Cai

Mark S Jensen

Wenjie Li

Mangzhu Zhao

Lihu Yang

Andrew S Thompson

Ralph P Volante

Michael J Martinelli

Changyou Zhou

Sheo B Singh

Edward J Grabowski

Young S Lo

Richard D Tillyer

David J Mathre

Dalian Zhao

David G Melillo

Lushi Tan

Steven A Weissman

Louis S Crocker

James A McCauley

Robert A Reamer

Paul O'Shea

Gerald S Brenner

Charles Bernard

Yuelie Lu

Nancy Sue Barta

Lucius Thomas Rossano

Xin Wang

Karen C Thompson

Min Ge

Jess Sager

Jean-Francois Marcoux

Oliver Thiel

Edward J J Grabowski

Fred Fleitz

Ashok Maliakal

Jennifer L Vandrilla

Masooma Tamim Raza

Anthony On-Ping King

Scott Hoerrner

Anthony King

Gary Javadi

Dorian Nelson

Tj Li

Elizabeth Szumigala

Timothy Bill

Thomas R Vernhoeven

Ji Liu

Laura E Fredenburgh

Hossain Jahansouz

Chen Y Cheng

Michael John Martinelli

The present invention relates to processes for preparing indoline derivatives, particularly 1-acetyl-6-amino-3,3-dimethyl-2,3-dihydroindole.

Method for the preparation of 1-acetyl-6-amino-3,3-dimethyl-2,3-dihydroindole

Methods of preparing cinacalcet, cinacalcet derivatives, and salts thereof is disclosed herein. Also disclosed herein are polymorphs of cinacalcet, compositions of cinacalcet, and methods of treating a subject by administering cinacalcet, wherein cinacalcet is prepared by the disclosed methods.

Methods of synthesizing cinacalcet and salts thereof

An efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl} cyclopentyl)[(3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine and its succinate salt are provided. The succinate salt is crystalline and has superior properties.

CCR-2 antagonist salt

The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro-2H-pyran-4-yl]amine and its succinate salt. The present invention additionally provides an efficient syntheses for the preparation of intermediates (3R)-3-methoxytetrahydro-4H-pyran-4-one; (1S,4S)-4-(2,5-dimethyl-1H-pyrrol-1-yl)-1-isopropylcyclopent-2-ene-1-carboxylic acid; and 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine; and for the preparation of the precursor (3S,4S)-N-((1S,4S)-4-isopropyl-4-{[3-(tri-fluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopent-2-en-1-yl)-3-methoxytetrahydro-2H-pyran-4-amine. The invention additionally resides in the superior properties of the succinate salt of ((1R,3S)-3-isopropyl-3-1{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine 

Process for the preparation of CCR-2 antagonists

A process for preparing a &bgr;-hydroxy carbamate product is disclosed. The process comprises reacting an olefin compound containing at least one carbon-carbon double bond with a carbamate in an aqueous solvent and in the presence of a base, an osmium catalyst, a co-oxidant selected from a halohydantoin, a haloisocyanuric acid, and an alkali metal salt of a haloisocyanuric acid, and optionally an asymmetric ligand, to form a reaction mixture containing the &bgr;-hydroxy carbamate product. The process optionally further comprises treating the &bgr;-hydroxy carbamate product with additional base to form an oxazolidinone. The oxazolidinones are useful as chiral auxiliary agents and as intermediates for the formation of pharmaceutically active substances such as alpha 1 a adrenergic receptor antagonists. A process for preparing nitrogen-functionalized derivatives of the oxazolidinones is also disclosed.

Process for preparing &bgr;-hydroxycarbamates and their conversion to oxazolidinones

The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.

Process for making diaryl pyridines useful as cox-2 inhibitors

This invention relates to crystalline pharmaceutically acceptable salts of an alpha 1a adrenergic receptor antagonist, Compound A, which are useful in the treatment of benign prostatic hyperplasia. Pharmaceutical compositions employing the crystalline salts, and processes for making and using the crystalline salts and pharmaceutical compositions of Compound A are also disclosed. This invention further relates to a process for obtaining enantiomerically pure intermediate useful for the synthesis of end product alpha 1a adrenergic receptor antagonists. The end product compounds are useful for the treatment of benign prostatic hyperplasia and for relaxing lower urinary tract tissue. The invention also relates to a process for preparing a class of dihydropyrimidinone compounds of which Compound A is a member, wherein the process involves deprotonating a dihydropyrimidinone compound and then coupling the deprotonated derivative with a primary amine.

Alpha 1a adrenergic receptor antagonists

This invention encompasses a novel process for synthesizing compounds represented by formula A:

Synthesis of methylthiophenyl hydroxyketones

Intermediates useful in a process for synthesizing COX-2 inhibitors

Process for making diaryl pyridines useful as COX-2 inhibitors

Described is a process of preparing 3-aryl, 4-aryloxy furan-5-ones which are useful as inhibitors of cyclooxygenase-2 (COX-2). Such compounds are useful as anti-inflammatory agents. The process is directed to an asymmetric synthesis which involves: a trisubstituted styrene derivative preparation via Horner-Wadsworth-Emmons reaction and subsequent one pot trifluoromethylation of the allylic alcohol; preparation of the .alpha.-hydroxyl ketone using Sharpless asymmetric dihydroxylation and Swern oxidation; the esterification of the .alpha.-hydroxyl ketone with the phenoxy acetic acid; and the Dieckman condensation of the resulting ester.

Process of making 3-aryloxy, 4-aryl furan-2-ones useful as inhibitors of

The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1##

Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2

The present invention is concerned with a novel linear process for the preparation of 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl) phenyl)-ethoxy)-4-(5-(dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S) -(4-fluorophenyl)-morpholine which is a potent and selective substance P (or neurokinin-1) receptor antagonist usefull as a therapeutic agent.

Linear process for the preparation of a morpholine compound

Process for making diaryl pyridines useful as cox-2-inhibitors

Process for synthesizing COX-2 inhibitors

Growing community of inventors

Bridgewater, NJ, United States of America

Robert D Larsen